Vanguard Group Inc. Sells 79,539 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

Vanguard Group Inc. lowered its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 1.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,389,216 shares of the company’s stock after selling 79,539 shares during the period. Vanguard Group Inc. owned about 0.06% of Arcus Biosciences worth $80,245,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Jane Street Group LLC boosted its holdings in Arcus Biosciences by 59.8% in the third quarter. Jane Street Group LLC now owns 217,041 shares of the company’s stock valued at $3,319,000 after acquiring an additional 81,193 shares during the last quarter. Barclays PLC boosted its stake in shares of Arcus Biosciences by 49.0% in the 3rd quarter. Barclays PLC now owns 118,693 shares of the company’s stock valued at $1,816,000 after purchasing an additional 39,015 shares during the last quarter. US Bancorp DE increased its position in shares of Arcus Biosciences by 2,432.0% during the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after buying an additional 6,615 shares during the period. KLP Kapitalforvaltning AS bought a new position in Arcus Biosciences during the fourth quarter worth $207,000. Finally, Amundi lifted its holdings in Arcus Biosciences by 137.0% in the fourth quarter. Amundi now owns 27,030 shares of the company’s stock valued at $403,000 after buying an additional 15,624 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Stock Down 5.7 %

Shares of NYSE RCUS opened at $7.49 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $18.98. The stock has a market capitalization of $786.96 million, a P/E ratio of -2.38 and a beta of 1.54. The company has a 50-day moving average price of $9.81 and a 200-day moving average price of $13.65.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.17) by $0.14. The firm had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. On average, equities research analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on RCUS shares. Morgan Stanley decreased their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Bank of America lowered their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. Finally, HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $18.00 to $24.00 in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Arcus Biosciences presently has a consensus rating of “Buy” and an average price target of $30.25.

Insider Buying and Selling at Arcus Biosciences

In other news, Director Yasunori Kaneko acquired 20,000 shares of Arcus Biosciences stock in a transaction on Thursday, February 27th. The stock was acquired at an average cost of $10.06 per share, with a total value of $201,200.00. Following the transaction, the director now owns 28,400 shares of the company’s stock, valued at approximately $285,704. This trade represents a 238.10 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Terry J. Rosen bought 19,800 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were purchased at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.